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Aim Edoxaban, a nonvitamin K antagonist oral
anticoagulant, is an oral factor Xa inhibitor approved for the
prevention of stroke and systemic embolism in adult
patients with atrial fibrillation and for the treatment and
secondary prevention in adult patients with venous
thromboembolism (VTE). This study details the design of
the Edoxaban Treatment in routiNe clinical prActice for
patients with Atrial Fibrillation in Europe (ETNA-AF-Europe)
study – a postauthorization observational study, which is
part of the postapproval plan for edoxaban agreed with the
European Medicines Agency.
Methods The ETNA-AF-Europe study (Clinicaltrials.gov:
NCT02944019) is a multicenter, prospective, observational
study that enrolled 13980 patients with atrial fibrillation
treated with edoxaban from 852 sites across 10 European
countries (Austria, Belgium, Germany, Ireland, Italy, the
Netherlands, Portugal, Spain, Switzerland, and the United
Kingdom). Patients treated with edoxaban were
prospectively enrolled and will be followed up for 4 years
with yearly follow-up visits.
Assessments The primary objective of the ETNA-AF-
Europe study is to assess the real-world safety of edoxaban
by evaluating bleeding events, including intracranial
hemorrhage; drug-related adverse events, such as hepatic
events; and cardiovascular and all-cause mortality. In
addition, efficacy will be assessed by recording major
adverse cardiovascular events including stroke, systemic
embolic events, transient ischemic attacks, and also VTE
episodes, acute coronary syndromes, and hospitalizations
related to cardiovascular condition. Event rates will be
compared with event rates reported in the PREvention oF
thromboembolic events-European Registry in Atrial
Fibrillation in atrial fibrillation (PREFER in AF) and PREFER
in AF Prolongation registries, and in the Effective
Anticoagulation with Factor Xa Next Generation in Atrial
Fibrillation – Thrombolysis in Myocardial Infarction 48 study
datasets.
J Cardiovasc Med 2019, 20:97–104
Keywords: atrial fibrillation, edoxaban, major bleeding, nonvitamin K
antagonist oral anticoagulants, real-world, registry, safety outcomes,
stroke prevention
aUniversity of Pisa, Pisa, Italy, bHRB Stroke Clinical Trials Network Ireland,
University College Dublin, Ireland, cCentro Hospitalar e Universita´rio de Coimbra,
Portugal, dHoˆpital de la Timone, Marseille, France, eUniversitair Ziekenhuis
Brussels, Belgium, fHospital Universitario La Paz, IDIPAZ, Madrid, Spain,
gWilhelminenhospital and Sigmund Freud University, Vienna, Austria, hUniversity
of Munster, Germany, iUniversity Hospital of Zurich, Switzerland, jAcademic
Medical Center/University of Amsterdam, The Netherlands, kUniversite´ Paris-
Dauphine, PSL Research University, Paris, France, lRoyal Free London NHS
Foundation Trust, Chase Farm Hospital, London, UK, mDaiichi Sankyo Europe
GmbH, Munich, Germany, nInstitute of Cardiovascular Sciences, University of
Birmingham, SWBH and UHB NHS Trusts, Birmingham, UK and oThe Atrial
Fibrillation NETwork (AFNET), Mu¨nster, Germany
Correspondence to Professor Raffaele De Caterina, Institute of Cardiology, Pisa
University Hospital, via Paradisa 2 - 56124 Pisa;
e-mail: raffaele.decaterina@unipi.it
Received 21 June 2018 Accepted 26 October 2018
Introduction
Atrial fibrillation is the most common sustained cardiac
arrhythmia in Europe, affecting approximately 2–3% of
the population.1,2 Atrial fibrillation is associated with
stroke, heart failure, dementia/cognitive impairment,
sudden death, and cardiovascular morbidity and mortal-
ity.3 A significant rise in the worldwide prevalence, inci-
dence, and overall burden of atrial fibrillation has been
noted in the past few decades, along with increasing
awareness, diagnostic tools, and therapies becoming
available.4
For several decades, vitamin K antagonists (VKAs), such
as warfarin, were the only oral anticoagulant drugs avail-
able for the prevention of stroke and systemic embolism
in atrial fibrillation patients. However, limitations, such as
the need for close monitoring and multiple food and drug
interactions, prompted the search for alternative antic-
oagulants with a stable pharmacology and easier use in
clinical practice. This resulted in the testing and approval
of non-VKA oral anticoagulants (NOACs). Edoxaban is
one of the four clinically available NOACs. It was
approved in Europe for stroke prevention in patients
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with atrial fibrillation, and also for the treatment and
prevention of venous thromboembolism (VTE). Edox-
aban is a highly selective, once-daily, direct, reversible
inhibitor of factor Xa. The recommended edoxaban dose
is 60mg once daily. A reduced dose of 30mg once daily is
required for patients with moderate or severe renal
impairment (creatinine clearance 15–50ml/min), low
body weight (60 kg), or concomitant use of strong P-
glycoprotein inhibitors including cyclosporine, dronedar-
one, macrolide antibiotics (erythromycin, clarithromy-
cin), or ketoconazole.5
The European Medicines Agency (EMA) approval of
edoxaban was based on pivotal studies, including the
Effective Anticoagulation with Factor Xa Next Genera-
tion in Atrial Fibrillation–Thrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) and Hokusai
VTE trials. The ENGAGE AF-TIMI 48 trial compared
edoxaban with warfarin in 21 105 patients with atrial
fibrillation, with a median 2.8 years of follow-up.6 Edox-
aban was noninferior to warfarin for the prevention of
stroke or systemic embolism, and caused less major
bleeding events compared with warfarin, despite excel-
lent time in therapeutic range in the warfarin arm. The
Hokusai VTE trial compared edoxaban with warfarin in
8292 patients with deep vein thrombosis or pulmonary
embolism after an initial treatment period with open-
label enoxaparin or unfractionated heparin for at least 5
days. Edoxaban was noninferior to dose-adjusted warfarin
for the prevention of recurrent VTE, and caused less
major or nonmajor clinically relevant bleeding.7
The EdoxabanTreatment in routiNe clinical prActice for
patients with nonvalvular Atrial Fibrillation Europe
(ETNA-AF-Europe) study was designed as part of the
risk management plan of edoxaban in order to assess the
risks and benefits of the drug in European patients with
atrial fibrillation. The design of ETNA-AF-Europe study
was agreed in close collaboration with the EMA as a
single-arm prospective international observational study.
The ETNA-AF-Europe registry is part of the global
ETNA initiative, which is composed of three regional
patient registries in Europe, East Asia, and Japan. The
ETNA-AF dataset is comparable with the earlier PRE-
vention oF thromboembolic events-European Registry in
Atrial Fibrillation (PREFER in AF)8 and PREFER in AF
Prolongation9 registries, and with the ENGAGE-TIMI
48 dataset. The aim of ETNA-AF-Europe study is to
collect real-world data on the safety and efficacy of
edoxaban in unselected patients with atrial fibrillation
and to compare event rates with these potential
comparator datasets.
Methods
Study design
The ETNA-AF-Europe study is a multinational, multi-
center, postauthorization, observational study (Clinical-
trials.gov: NCT02944019) conducted at 852 sites from 10
European countries (Austria, Belgium, Germany, Ireland,
Italy, TheNetherlands, Portugal, Spain, Switzerland, and
United Kingdom). The final ETNA-AF protocol was
developed based on discussions with the Pharmacovigi-
lance Risk Assessment Committee (PRAC) of the EMA,
and finally approved by them. Patients will be followed
up for 4 years. In line with a study collecting information
in clinical routine, this observational study has broad
inclusion and exclusion criteria (Table 1). Study protocol
approvals were provided by Competent Authorities, and
central and local Ethics Committees for each participat-
ing site in all countries involved.
Because the ETNA-AF-Europe study will be put into
perspective with PREFER in AF and PREFER in AF
Prolongation registries, only countries included in the
PREFER registry program were allowed. Because the
registry focuses on edoxaban, only countries in which
edoxaban is currently reimbursed were selected.
The ETNA-AF-Europe study is part of the global ETNA
program, which consists of regionally-sponsored and con-
ducted registries, including those conducted in Japan,
Europe, and South Central Asia. Each regional protocol is
developed to optimally reflect the respective regulatory
requirements of the regions, and therefore with specific
differences, but harmonized concerning the core data to
be collected. All regional core data will be therefore
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Table 1 Inclusion and exclusion criteria in ETNA-AF-Europe, PREFER in AF, and ENGAGE AF-TIMI 48 studies
ETNA-AF-Europe PREFER in AF8 ENGAGE AF-TIMI 486
Inclusion criteria Adult patients will be eligible for inclusion if:
They provide written informed consent to
participate,
Are treated with edoxaban for AF according
to the edoxaban summary of product
characteristics, and
Are not simultaneously participating in any
interventional study
Adult patients were eligible for inclusion if:
They gave written informed consent for
participation in the registry
They had a confirmed diagnosis of AF according
to the 2010 ESC guidelines,19 as documented
by electrocardiography or an implanted
pacemaker or defibrillator within the preceding
12 months
Suspected, but unconfirmed, AF cases were not
eligible
Adult patients were eligible for inclusion
if
They were aged21 years and were able
to provide written informed consent
Had a history of AF documented by any
electrical tracing within the prior 12
months and for which ACT is indicated
and planned for the duration of the
study
Had a CHADS2 index score 2
Exclusion criteria No other explicit exclusion criteria will be set
to avoid selection bias and to allow
documentation of routine clinical practice
No explicit exclusion criteria were defined in order
to avoid selection bias and to achieve a cohort
close to ‘real life’
A long list of exclusion criteria were
applied
ACT, anticoagulation therapy; AF, atrial fibrillation.
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integrated into one global database, but will also be
analyzed regionally.
Objectives and outcome measures
The primary objective of the study is to assess the real-
world safety of edoxaban by evaluating bleeding events,
including intracranial hemorrhage; drug-related adverse
events, such as liver adverse events; and cardiovascular
and all-cause mortality in atrial fibrillation patients trea-
ted with edoxaban up to 4 years, with regard to onset
(relative to treatment with edoxaban) of the event, dura-
tion, severity, and outcomes. Events of special impor-
tance (major bleeding events, strokes, systemic embolic
events, and deaths) will be adjudicated by an indepen-
dent clinical event adjudication committee.
The results will be compared with existing datasets,
namely the PREFER in AF and PREFER in AF Pro-
longation registries, and the ENGAGE AF-TIMI 48 trial
dataset. These databases have used highly harmonized
endpoint definitions, and will therefore provide compar-
ative data for patients treated with other anticoagulants.
Secondary outcomes include the following:
(1) Stroke (ischemic and hemorrhagic)
(2) Systemic embolic events (SEEs)
(3) Transient ischemic attack
(4) Major adverse cardiovascular events (MACE), a
composite endpoint of nonfatal myocardial infarc-
tion, nonfatal stroke, nonfatal SEE, and death due to
cardiovascular cause or bleeding
(5) VTE episodes
(6) Acute coronary syndromes
(7) Hospitalizations related to cardiovascular condition
(8) Extent of exposure and compliance to edoxaban
therapy, rate, and reasons of permanent discontinua-
tion of edoxaban.
Results related to the secondary objectives will also be
compared with external databases (PREFER in AF,
PREFER in AF Prolongation and ENGAGE AF-TIMI
48 trial) along similar lines as for the data related to
primary objectives. Findings from ETNA-AF-Europe
after 1, 2, and 3 years, respectively, will be compared
with results after 1 year (and 2 years, where applicable)
from the PREFER in AF and the PREFER in AF
Prolongation registries, and also with the results after 3
years from the ENGAGE AF-TIMI 48 trial.
Inclusion and exclusion criteria
Inclusion and exclusion criteria are listed in Table 1
alongside the criteria applied in the PREFER in AF
registry and ENGAGE AF-TIMI 48 trial. Sites were
required to complete a patient screening log of eligible
patients for the registry at their treatment centers to
assess the representativeness of the study population.
Patients who discontinue edoxaban during the
observation period will be followed up annually for a
further 2 years or until the end of the study, whichever
comes first.
Study periods
The patient recruitment period is scheduled for 12
months, followed by a 48-month follow-up period per
patient on edoxaban treatment. Documentation of
patient data will be offered at five time-points: at baseline
(at enrolment); at follow-up 1: 12 2 months after base-
line; at follow-up 2: 24 2 months after baseline; at
follow-up 3: 36 2 months after baseline; and at fol-
low-up 4: 48 2 months after baseline (Fig. 1).
At baseline, the patients’ medical and treatment history is
collected. At each annual follow-up, changes in therapy
and disease status since the last documentation will be
recorded. At the time of the final assessment, the physi-
cian will be requested to enter the patient’s vital status. It
will be the responsibility of the investigators and their
staff to enter all relevant patient data required for this
study in the electronic case report form (eCRF) and
patients’ medical records. The final assessment will
include date of final assessment, reason for final assess-
ment (i.e. end of observational period reached – either 4
years or after two data collection points after discontinu-
ation of edoxaban), withdrawal of consent, death, transfer
to another institution, lost to follow-up), and intended
further treatment for atrial fibrillation.
Patient memory aids are being distributed to patients to
record all information throughout the year; these aids
should support patients to recall important issues in the
interval between two follow-up data collection points, as
events will not trigger unplanned follow-up visits.
Definitions
All variables in the ETNA-EU-Europe study are defined
as closely as possible to those in the PREFER in AF
registry program8 and ENGAGE AF-TIMI 48 interven-
tional study6 to allow comparability of outcomes. A list of
definitions is included in Supplementary Table S1
(http://links.lww.com/JCM/A149).
Site selection
About 1500 physicians (56.5% of hospital-based and
42.8% of office-based cardiologists, general practitioners,
internists, and neurologists) are participating in the study.
Different databases were used to identify a broad list of
potential sites. At least three times the targeted number
of active sites were contacted by sending a site qualifica-
tion questionnaire to be completed.
A stepwise process for site selection was performed to
allow representative regional distribution of sites and site
specialties. Geographic representativeness within the
country was maintained as sites were selected from each
province and language region, where applicable. To
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account for site characteristics representativeness, a ratio
of 40% of cardiologists, 40% of general practitioners, and
20% of internal medicine and other specialists were
specified per country. Site selection criteria are given
in Table 2.
Considering that ETNA-AF-Europe is a noninterven-
tional study, all prescriptions are solely at the discretion
of the treating physicians.
Data collection
The scheduled documentation time-points are listed in
Table 3. All data elements are being collected from
information routinely recorded in the medical records.
No additional visits or examinations, laboratory tests, or
procedures are mandated as part of this study in line with
the PRAC process not to influence routine clinical prac-
tice. Data from routine patient data collection points at
each respective site will be documented directly in the
medical records and shortly thereafter updated in the
eCRFs, which will be uploaded to the secure, internet-
based Medidata Rave electronic data capture system.
Data management plan
The Medidata Rave EDC system will be used for data
capture. Data will be collected in standardized English
eCRFs. A data management plan will be created in the
study start phase and will describe all functions, pro-
cesses, and specifications for data collection, cleaning,
and validation. The data validation includes programmed
edit checks and manual checks of the following:
(1) Checks for missing and/or incomplete data
(2) Checks on nonconformance (e.g. a nonexisting date
or a numeric field including text)
(3) Range checks on numeric fields (e.g. a field that has
to be greater than x but lower than y)
(4) Checks for missing values (e.g. a predetermined
required field)
(5) Checks for future dates
(6) Checks across different data items within one CRF
module, between CRF modules, across visits on
consistency of documentation.
Quality control
The study is being conducted according to the Good
Pharmaco-epidemiology Practice and Guideline on good
pharmacovigilance practices (Module VIII EMA/813938/
100 Journal of Cardiovascular Medicine 2019, Vol 20 No 2
Table 2 Criteria for a site to be selected for participation in the
study
Site selection criteria
The site should have access to patients with AF that may be treated with edoxaban
The site should be able to document the data in English language
The site should be able to complete the study in the electronic data capture system
The site should be able to conduct the study adequately, with enough time and
staff to identify eligible patients, conduct the patient consent process,
participate in required trainings, enter study data, and follow-up with study
related activities
The site should agree to follow-up patients for a period of four years per patient
according to clinical routine
AF, atrial fibrillation.
Fig. 1
(S)ADR, (serious) adverse drug reaction; BL, baseline; FU, follow-up
BL FU1 FU2
•
•
FU3 FU4
In case of permanent disconnuaon of edoxaban:
Further 2 annual FU of paents or unl end of 4 year
FU-period, whatever comes ﬁrst
Annual FU me points remain unchanged
0 12 ± 2 24 ± 2 36 ± 2 48 ± 2 months
Paent inclusion
(S)ADR reporng on an on-going basis according to spontaneous reporng melines
Study schedule.
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2011 Rev 1). Related quality control mechanisms, includ-
ing data plausibility checks and monitoring of data, will
be performed accordingly. Onsite monitoring is being
performed in randomly selected sites (30%) including
100% check of informed consents and source data verifi-
cation of up to three patients per visited site. Remote
quality checks will be done using both automated and
manual queries. Data quality checks will be performed on
an ongoing basis. Particular attention will be given to the
completeness and correctness of safety data. These pro-
cesses are homologous to the quality control in PREFER
in AF.
Sample size calculations
The sample size calculations are based on the incidence
rate of intracranial hemorrhages (ICHs), as this has the
lowest incidence amongst the event rates of interest
(major bleeding, ischemic stroke, and ICH). Taking
the real-life situation into account, the event rate for
ICH was assumed at 0.35% per year. Over 4 years, this
results in a rate of 1.4%. To estimate the 95% confidence
interval (CI) with a precision range from 0.25% for the
rate at 1.4% (corresponding to a relative precision of
17.8%), 8485 patients are needed. Assuming a dropout
rate of approximately 35% over the 4 years, approxi-
mately 13 100 patients were estimated as needed to be
enrolled for a reasonable estimation of the event rate.
To increase the study power for the primary safety
analysis and to address the spectrum of indications for
edoxaban, the ETNA-AF-Europe data will be combined
with the safety data from the parallel edoxaban study
ETNA-VTE-Europe, which plans to recruit 2700
patients to be followed up for 18 months.10 Together,
these studies will enroll approximately 15 800 patients,
with a combined expected 18-month dropout rate of 20%.
Consequently, data for approximately 12 640 patients
should be available at 18 months to assess the incidence
rates of interest [i.e. major bleeding, mortality and
adverse drug reactions (ADRs)]. This combined analysis
should provide sufficient statistical power to capture
uncommon ADRs with low incidence rates. For example,
for those with incidence rates between 0.1 and 1.0%, the
corresponding 95% CIs will range between 0.06 and
0.17%.
Statistical analysis
All analyses will be defined prospectively in a statistical
analysis plan. The following analyses are planned: a final
analysis of ETNA-AF-Europe; a comparison of ETNA-
AF-Europe with the results of the PREFER in AF and
the ENGAGE AF-TIMI 48 datasets; a combined safety
analysis of ETNA-AF-Europe and ETNA-VTE-Europe
based on the 18-month safety data of both the studies.
Five data snapshots will be performed after approxi-
mately 1, 2, 3, and 4 years of mean enrolment: quarter
(Q) 4 2017, Q4 2018, Q4 2019, Q4 2020, and Q4 2021.
All computations and generations of tables will be per-
formed using the SAS version 9.3 or higher (SAS Insti-
tute, Cary, North Carolina, USA). Exploratory/
descriptive statistics will be used to perform the analyses.
Categorical variables will be summarized by the number
and percentage (%) of patients in each category.
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Table 3 Time points for data collection
Baseline FU1 FU2 FU3 FU4
CRFs
Date X X X X X
Eligibility X
Demographics X
Physical examination
Vital signs (BP, HR, height, and weight) X X X X X
AF disease
Medical history (relevant comorbidities) X
Disease history (first diagnosis, events)a X
AF diagnosis as availablea X X X X X
Laboratory parameters as available X X X X X
AF symptoms X X X X X
AF related clinical events and hospitalisationsb X X X X X
AF-related interventionsa X X X X
AF therapy
AF-related previous therapy (medications, interventions)c X
Edoxaban therapy (history/current/since last data collection point)c X X X X X
Nonedoxaban AF-related therapy X X X X X
Physician judgement on compliance to edoxaban therapyd (X)e X X X X
ADR reporting for edoxaban Continuously
Final assessmentf At final FU or early study termination
ADR, adverse drug reaction; AF, atrial fibrillation; BL, baseline; BP, blood pressure; CRFs, case report forms; FU, follow-up; HR, heart rate. a Type of AF, date of first
diagnosis, symptoms at first diagnosis and current, ECHO; type of interventions, date and number of interventions. b Event date, type, location if applicable, severity,
outcomes of stroke, transient ischaemic attack, other bleeding events, acute coronary syndrome, chronic heart failure, systemic embolism, venous thromboembolic event,
malignancies, others. c Past and current therapy; start and stop dates, dosage and frequency. d Optional data, reported by investigator and patient. e If patient is not
edoxaban naı¨ve. f The final assessment includes date of final assessment, reason for final assessment [i.e. end of observational period reached (either 4 years or after two
data collection points after discontinuation of edoxaban), withdrawal of consent, death, transfer to another institution, lost to follow-up] and intended further treatment for AF.
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Continuous variables will be summarized using number
of nonmissing/missing observations, mean, standard devi-
ation (SD), median, first and third quartile, and mini-
mum/maximum values. The 95% CIs will also be
provided for selected variables. Whenever applicable,
Kaplan–Meier analysis will be performed to illustrate
risk over time.
Time-to-event variables will be analyzed by a Cox pro-
portional-hazard regression model, presenting hazard
ratios, and corresponding 95% CIs and P values for
comparisons of the predefined subgroups. All Coxmodels
will include the CHA2DS2-VASc score as an additional
covariate. Based on the results in the PREFER registry
program and the ENGAGE AF-TIMI 48 trial, no further
confounders are considered upfront. Nevertheless, if any
relevant differences in baseline characteristics are
detected, these variables will be added to the model as
additional covariates.
All comparisons between ETNA-AF data and the data
from the PREFER in AF disease registry program and
the contextualization of outcomes versus ENGAGE AF-
TIMI 48 trial will be explorative.
Study status
The enrolment started in May 2015 in Switzerland and in
August 2015 in Germany; however, in agreement with the
newly formed PRAC, it was stalled to integrate the input
from PRAC. The study protocol was revised according to
the guidance received from the PRAC, mandated by
changes in EMA legislation and a revised PRAC process
that was notified in July 2015. This process delayed enroll-
ment by approximately 1 year. Patient enrollment resumed
in Germany, Ireland, The Netherlands, Switzerland, and
United Kingdom in November 2016, and in Austria,
Belgium, Italy, Portugal, and Spain in Q1 of 2017.
Discussion
The ETNA-AF-Europe and the global ETNA program
will provide ‘real-world’ efficacy and safety data on
edoxaban use in a wide range of European countries
and diverse clinical settings mandated by EMA. Findings
from this registry will complement the results of pivotal
trials through the use of unselected real-world patient
population. The design of ETNA-AF-Europe study will
be put into perspective with the data from the PREFER
in AF and PREFER in AF Prolongation registries, with
highly harmonized sites and methods of data collection.
Because the PREFER registries enrolled patients treated
with a range of oral anticoagulants, analyses on different
treatments including NOACs, VKAs, and antiplatelet
agents as monotherapy or in combinations (for Europe
and per country) can be conducted. In addition, the
results obtained in the ETNA-AF-Europe study will
be put in relation with the results of the ENGAGE
AF-TIMI 48 study to reflect similarities and differences
between noninterventional and interventional settings of
the two studies. These will include the discontinuation
rates experienced in the PREFER in AF registry and
ENGAGE AF-TIMI trial, which may be useful for a
comparison with the real-life patient adherence in the
ETNA-AF registry. In all, the variables and approaches
used for ETNA-AF-Europe are defined as close as pos-
sible to the ones used in PREFER in AF/ENGAGE AF-
TIMI 48 and as feasible in a noninterventional trial to
allow a meaningful comparison.
In addition, the design of the Xarelto for Prevention of
Stroke in Patients With Atrial Fibrillation (XANTUS)
study was also taken into consideration while designing
ETNA-AF-Europe.11 The XANTUS study – a real-
world, prospective, observational study of patients trea-
ted with rivaroxaban for stroke prevention in atrial fibril-
lation – was similar in design (noninterventional,
nonrandomized, single-arm postauthorization safety
study) and size (7000 patients), and investigated similar
objectives, namely the safety and efficacy of rivaroxaban
in a real-world setting.
Collection of real-world data for anticoagulants, as for any
new drug in general, is vital because of the need for
obtaining valuable information additional to what is col-
lected in the setting of clinical trials. The latter select
patients using stringent inclusion and exclusion criteria,
and patients are followed up very closely to ensure adher-
ence to drug regimens, which does not occur once the drug
is released in the market. In addition, the spectrum of
patients effectively treated once the drug is released in the
market is wider than that used in the registered trials,
because of the off-label use for a variety of patients.
Regarding oral anticoagulants, many countries are seem-
ingly on the verge of a large shift from VKAs to NOACs as
the preferred choice for thrombosis prophylaxis, with
NOACs now being highly adopted into practice and
already becoming prescribed more frequently than
VKAs.12,13 Notably, data available from other registries,
such as Global Anticoagulant Registry in the FIELD–
Atrial Fibrillation14 and Global Registry on Long-Term
Oral Antithrombotic Treatment in Patients with Atrial
Fibrillation,15 have provided insights into the evolution
of global anticoagulation practice and the increasing use
of NOACs. This raises important questions that can only
be addressed in datasets that are close to routine practice,
for example, attrition and discontinuation rates on ther-
apy, adequacy of dosing and relationship of inadequate
dosing to outcomes, and regional patterns of NOAC use,
including effects of different healthcare systems and
socioeconomic environments. Initial data from Europe
suggest that the treatment benefits of NOAC therapy are
preserved in routine care.11,16–18 The ETNA-AF-Europe
study will further contribute important information on
the management of atrial fibrillation patients in routine
care, NOACs in general, and the risks and benefits
associated with edoxaban.
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The strengths of the ETNA-AF-Europe noninterven-
tional registry include the prospective design, large sam-
ple size, inclusion of patients from different clinical
settings, predefined endpoints, rigorous data collection,
prolonged follow-up, and that it ‘nests’ within a global
registry program with harmonized outcome definitions.
The independent adjudication of events of special impor-
tance is expected to reduce reporting and misclassifica-
tion bias. While the PRAC process delayed the start of
ETNA-AF, the stringent planning will add to the quality
of the data coming from its analysis.
Some limitations common to noninterventional studies
are, however, present, mostly related to the nonrandom-
ized nature of the study. Because patients treated with
edoxaban before baseline, but not receiving the drug at
baseline, are not eligible for inclusion in this study, a
possible ‘selection bias’ of patients cannot be excluded.
However, it must be noted that this bias cannot be
excluded in any other noninterventional study focusing
on a new drug category, including all registries with
NOACs. For the success of the study, it is vital that all
sites have sufficient recruitment capability, the capacity
to participate in this postauthorization observational
study, and are then able to follow-up patients for 4 years.
Due to the long time between two data collection points,
it is possible that some data may be under-reported by
participating patients, or there may be potential chances
of misclassification of treatment changes and concomitant
drug exposure. However, this risk is considered to be low,
as relevant treatment changes are usually precisely docu-
mented in medical records, the eCRF, and often in
patient memory aids. Finally, there will be a need to
take the regional differences into consideration while
evaluating the persistence of edoxaban.
Conclusions
The ETNA-AF-Europe registry will provide valuable
data on the real-world use of edoxaban in Europe. More-
over, the safety of edoxaban and some clues to its efficacy
in the general population of atrial fibrillation patients will
be assessed over a period of 4 years. International trends
of edoxaban usage and persistence may be of interest and
may determine the value of the latest once a day NOAC
to be approved for stroke prevention in patients with AF.
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